KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Income: 2009-2024

Historic Operating Income for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $4.0 billion.

  • Regeneron Pharmaceuticals' Operating Income fell 12.95% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 7.18%. This contributed to the annual value of $4.0 billion for FY2024, which is 1.39% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Operating Income stood at $4.0 billion for FY2024, which was down 1.39% from $4.0 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Operating Income ranged from a high of $8.9 billion in FY2021 and a low of $3.6 billion during FY2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Operating Income value was $4.0 billion (recorded in 2023), while the average stood at $4.3 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Operating Income skyrocketed by 150.15% in 2021, and later slumped by 47.03% in 2022.
  • Regeneron Pharmaceuticals' Operating Income (Yearly) stood at $3.6 billion in 2020, then surged by 150.15% to $8.9 billion in 2021, then tumbled by 47.03% to $4.7 billion in 2022, then decreased by 14.60% to $4.0 billion in 2023, then dropped by 1.39% to $4.0 billion in 2024.